keyword
MENU ▼
Read by QxMD icon Read
search

ravi madan

keyword
https://www.readbyqxmd.com/read/29877103/spotlight-on-atezolizumab-and-its-potential-as-an-oncology-agent
#1
Jason M Redman, Ravi A Madan
No abstract text is available yet for this article.
June 7, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29852171/mechanisms-involved-in-epigenetic-down-regulation-of-gfap-under-maternal-hypothyroidism
#2
Praveen Kumar, Nachiket M Godbole, Chandra P Chaturvedi, Ravi S Singh, Nelson George, Aditya Upadhyay, B Anjum, Madan M Godbole, Rohit A Sinha
Thyroid hormones (TH) of maternal origin are crucial regulator of mammalian brain development during embryonic period. Although maternal TH deficiency during the critical periods of embryonic neo-cortical development often results in irreversible clinical outcomes, the fundamental basis of these abnormalities at molecular level is still obscure. One of the key developmental process affected by maternal TH insufficiency is the delay in astrocyte maturation. Glial fibrillary acidic protein (Gfap) is a predominant cell marker of mature astrocyte and is regulated by TH status...
May 28, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29685393/notification-and-counselling-of-hepatitis-positive-blood-donors-their-immediate-emotional-response-contact-testing-and-their-follow-up-study-from-a-tertiary-care-hospital
#3
Aseem K Tiwari, Gunjan Bhardwaj, Ravi C Dara, Dinesh Arora, Geet Aggarwal, Richa Bhargava, Kaushal Madan
INTRODUCTION: Post-donation counselling informs donors of unusual test results. Timely notification and counselling regarding their Transfusion Transmitted Infection (TTI) status is necessary for early clinical intervention in the donor and reducing risk of transmission. We share our experience with respect to Hepatitis B (HBV) and Hepatitis C (HCV) positive donors who were counselled and followed-up for clinical outcome. MATERIALS AND METHODS: It was prospective 2-year study in TTI positive blood donors...
April 13, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29602821/a-prospective-comparison-of-18-f-sodium-fluoride-pet-ct-and-psma-targeted-18-f-dcfbc-pet-ct-in-metastatic-prostate-cancer
#4
Stephanie A Harmon, Ethan Bergvall, Esther Mena, Joanna H Shih, Stephen Adler, Yolanda McKinney, Sherif Mehralivand, Deborah E Citrin, Anna Couvillon, Ravi Madan, James Gulley, Ronnie C Mease, Paula M Jacobs, Martin G Pomper, Baris Turkbey, Peter L Choyke, M Liza Lindenberg
Purpose: The purpose of this study was to compare the diagnostic performance of 18 F-DCFBC positron emission tomography/computed tomography (PET/CT), a first generation 18 F-labelled prostate-specific membrane antigen (PSMA)-targeted agent, and 18 F-NaF PET/CT, a sensitive marker of osteoblastic activity, in a prospective cohort of patients with metastatic prostate cancer. Methods: Twenty-eight prostate cancer patients with metastatic disease on conventional imaging prospectively received up to four PET/CT scans...
March 30, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29582792/perspectives-on-the-clinical-development-of-immunotherapy-in-prostate-cancer
#5
REVIEW
Lisa M Cordes, James L Gulley, Ravi A Madan
Despite impressive survival benefits with immunotherapy in patients with various solid tumors, the full potential of these agents in prostate cancer has yet to be realized. Sipuleucel-T demonstrated a survival benefit in this population, indicating that prostate cancer is an immunoresponsive disease; however, these results have not been matched by other agents. A large trial with ipilimumab in prostate cancer failed to meet its primary objective, and small trials with PD-1/PD-L1 inhibitors did not yield a significant improvement in overall response...
May 2018: Asian Journal of Andrology
https://www.readbyqxmd.com/read/29536949/the-path-forward-in-prostate-cancer-therapeutics
#6
EDITORIAL
Jeanny B Aragon-Ching, Ravi A Madan
No abstract text is available yet for this article.
May 2018: Asian Journal of Andrology
https://www.readbyqxmd.com/read/29520448/targeting-the-tumor-microenvironment-with-immunotherapy-for-genitourinary-malignancies
#7
REVIEW
Ariel E Marciscano, Ravi A Madan
Bacillus Calmette-Guérin in urothelial carcinoma, high-dose interleukin-2 in renal cell carcinoma, and sipuleucel-T in prostate cancer serve as enduring examples that the host immune response can be harnessed to promote effective anti-tumor immunity in genitourinary malignancies. Recently, cancer immunotherapy with immune checkpoint inhibitors has transformed the prognostic landscape leading to durable responses in a subset of urothelial carcinoma and renal cell carcinoma patients with traditionally poor prognosis...
March 8, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29298798/phase-i-trial-of-m7824-msb0011359c-a-bifunctional-fusion-protein-targeting-pd-l1-and-tgf%C3%AE-in-advanced-solid-tumors
#8
Julius Strauss, Christopher R Heery, Jeffrey Schlom, Ravi A Madan, Liang Cao, Zhigang Kang, Elizabeth Lamping, Jennifer L Marté, Renee N Donahue, Italia Grenga, Lisa Cordes, Olaf Christensen, Lisa Mahnke, Christoph Helwig, James L Gulley
Purpose: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ "trap." Experimental Design: In the 3+3 dose-escalation component of this phase I study (NCT02517398), eligible patients with advanced solid tumors received M7824 at 1, 3, 10, or 20 mg/kg once every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal; in addition, a cohort received an initial 0.3 mg/kg dose to evaluate pharmacokinetics/pharmacodynamics, followed by 10 mg/kg dosing...
March 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29219670/expanding-the-use-of-abiraterone-in-prostate-cancer-is-earlier-always-better
#9
Keith T Schmidt, Ravi A Madan, William D Figg
No abstract text is available yet for this article.
February 1, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29146441/combining-immunotherapies-for-the-treatment-of-prostate-cancer
#10
REVIEW
Jason M Redman, James L Gulley, Ravi A Madan
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great promise for improving outcomes for prostate cancer patients. Here we review the latest developments in immunotherapy for prostate cancer. Sipuleucel-T has demonstrated a survival advantage of 4.1 months in metastatic castration-resistant prostate cancer. PSA-TRICOM (PROSTVAC), a prostate-specific antigen-targeted vaccine platform, showed evidence of clinical and immunologic efficacy in early-phase clinical trials, and results from a phase III trial in advanced disease are pending...
December 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28906538/nuclear-cardiology-practices-and-radiation-exposure-in-africa-results-from-the-iaea-nuclear-cardiology-protocols-study-incaps
#11
Salah E Bouyoucef, Mathew Mercuri, Thomas N Pascual, Adel H Allam, Mboyo Vangu, João V Vitola, Nathan Better, Ganesan Karthikeyan, John J Mahmarian, Madan M Rehani, Ravi Kashyap, Maurizio Dondi, Diana Paez, Andrew J Einstein
OBJECTIVE: While nuclear myocardial perfusion imaging (MPI) offers many benefits to patients with known or suspected cardiovascular disease, concerns exist regarding radiation-associated health effects. Little is known regarding MPI practice in Africa. We sought to characterise radiation doses and the use of MPI best practices that could minimise radiation in African nuclear cardiology laboratories, and compare these to practice worldwide. METHODS: Demographics and clinical characteristics were collected for a consecutive sample of 348 patients from 12 laboratories in six African countries over a one-week period from March to April 2013...
July 2017: Cardiovascular Journal of Africa
https://www.readbyqxmd.com/read/28855356/phase-i-study-of-a-poxviral-tricom-based-vaccine-directed-against-the-transcription-factor-brachyury
#12
Christopher R Heery, Claudia Palena, Sheri McMahon, Renee N Donahue, Lauren M Lepone, Italia Grenga, Ulrike Dirmeier, Lisa Cordes, Jenn Marté, William Dahut, Harpreet Singh, Ravi A Madan, Romaine I Fernando, Duane H Hamilton, Jeffrey Schlom, James L Gulley
Purpose: The transcription factor brachyury has been shown in preclinical studies to be a driver of the epithelial-to-mesenchymal transition (EMT) and resistance to therapy of human tumor cells. This study describes the characterization of a Modified Vaccinia Ankara (MVA) vector-based vaccine expressing the transgenes for brachyury and three human costimulatory molecules (B7.1, ICAM-1, and LFA-3, designated TRICOM) and a phase I study with this vaccine. Experimental Design: Human dendritic cells (DC) were infected with MVA-brachyury-TRICOM to define their ability to activate brachyury-specific T cells...
November 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28752121/docetaxel-extravasation-pathologic-correlation-and-treatment-with-intralesional-steroids
#13
John W Roman, Michelle A Ojemuyiwa, Lisa M Cordes, Ravi A Madan, Leonard Sperling
No abstract text is available yet for this article.
July 2017: JAAD Case Reports
https://www.readbyqxmd.com/read/28679644/a-phase-ii-multi-center-study-of-bevacizumab-in-combination-with-ixabepilone-in-subjects-with-advanced-renal-cell-carcinoma
#14
MULTICENTER STUDY
Mauricio Burotto, Maureen Edgerly, Margarita Velarde, Sanjeeve Balasubramaniam, Harry Drabkin, Juan G Gormaz, Ciara O'Sullivan, Ravi Madan, Tito Fojo
LESSONS LEARNED: Accrual to renal cell carcinoma trials remains a challenge despite the lack of prolonged response to the available treatments.The observation of three responses among the 30 patients with median progression-free survival and overall survival of 8.3 and 15 months, respectively, indicates the combination has some activity, but it is not sufficient for further development. BACKGROUND: Treatment of metastatic renal cell carcinoma (mRCC) remains suboptimal...
August 2017: Oncologist
https://www.readbyqxmd.com/read/28663235/immunotherapy-of-prostate-cancer-facts-and-hopes
#15
REVIEW
Marijo Bilusic, Ravi A Madan, James L Gulley
In the last few years, immunotherapy has become an important cancer treatment modality, and although the principles of immunotherapy have evolved over many decades, the FDA approvals of sipuleucel-T and ipilimumab began a new wave in immuno-oncology. Despite the current enthusiasm, it is unlikely that any of the immunotherapeutics alone can dramatically change prostate cancer outcomes, but combination strategies are more promising and provide a reason for optimism. Several completed and ongoing studies have shown that the combination of cancer vaccines or checkpoint inhibitors with different immunotherapeutic agents, hormonal therapy (enzalutamide), radiotherapy (radium 223), DNA-damaging agents (olaparib), or chemotherapy (docetaxel) can enhance immune responses and induce more dramatic, long-lasting clinical responses without significant toxicity...
November 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28644303/prostate-cancer-immunotherapy-the-path-forward
#16
Ravi A Madan, James L Gulley
PURPOSE OF REVIEW: To provide an overview of current strategies being investigated in the development of immunotherapy in prostate cancer. RECENT FINDINGS: Development of immunotherapy in prostate cancer actually began in 2010 with FDA approval of sipuleucel-T. Given that immune checkpoint inhibitor trials have either been negative at the phase III level or underwhelming in smaller studies, it is likely that combination strategies will be required to further maximize the impact immune-based therapies on the clinical course of the disease...
September 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28534538/prostate-cancer-better-vistas-ahead-potential-and-pitfalls-of-immunotherapy
#17
Ravi A Madan, James L Gulley
No abstract text is available yet for this article.
August 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28434181/management-options-for-biochemically-recurrent-prostate-cancer
#18
REVIEW
Farhad Fakhrejahani, Ravi A Madan, William L Dahut
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging. For these patients with biochemical recurrent prostate cancer, there is no uniform guideline for subsequent management. Based on available data, it seems prudent that biochemical recurrent prostate cancer should initially be evaluated for salvage radiation or prostatectomy, with curative intent...
May 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28376158/role-of-antigen-spread-and-distinctive-characteristics-of-immunotherapy-in-cancer-treatment
#19
REVIEW
James L Gulley, Ravi A Madan, Russell Pachynski, Peter Mulders, Nadeem A Sheikh, James Trager, Charles G Drake
Immunotherapy is an important breakthrough in cancer. US Food and Drug Administration-approved immunotherapies for cancer treatment (including, but not limited to, sipuleucel-T, ipilimumab, nivolumab, pembrolizumab, and atezolizumab) substantially improve overall survival across multiple malignancies. One mechanism of action of these treatments is to induce an immune response against antigen-bearing tumor cells; the resultant cell death releases secondary (nontargeted) tumor antigens. Secondary antigens prime subsequent immune responses (antigen spread)...
April 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28373007/avelumab-for-metastatic-or-locally-advanced-previously-treated-solid-tumours-javelin-solid-tumor-a-phase-1a-multicohort-dose-escalation-trial
#20
Christopher R Heery, Geraldine O'Sullivan-Coyne, Ravi A Madan, Lisa Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L Marté, Lauren M Lepone, Renee N Donahue, Italia Grenga, Jean-Marie Cuillerot, Berend Neuteboom, Anja von Heydebreck, Kevin Chin, Jeffrey Schlom, James L Gulley
BACKGROUND: Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to PD-L1, inhibiting its binding to PD-1, which inactivates T cells. We aimed to establish the safety and pharmacokinetics of avelumab in patients with solid tumours while assessing biological correlatives for future development. METHODS: This open-label, single-centre, phase 1a, dose-escalation trial (part of the JAVELIN Solid Tumor trial) assessed four doses of avelumab (1 mg/kg, 3 mg/kg, 10 mg/kg, and 20 mg/kg), with dose-level cohort expansions to provide additional safety, pharmacokinetics, and target occupancy data...
May 2017: Lancet Oncology
keyword
keyword
40866
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"